Parkinson's Drug Entacapone Disrupts Gut Microbiome Through Iron Deficiency
A study reveals that the Parkinson's drug entacapone disrupts the gut microbiome by inducing iron deficiency, promoting the growth of harmful bacteria like E. coli. This highlights the broader impact of human-targeted drugs on microbial health and suggests that targeted iron supplementation could mitigate these effects. The findings emphasize the need for microbiome-conscious drug designs to improve treatment outcomes.